High dose image-guided, intensity modulated radiation therapy (IG-IMRT) for chordomas of the sacrum, mobile spine and skull base: preliminary outcomes

Carregando...
Imagem de Miniatura
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Citação
JOURNAL OF NEURO-ONCOLOGY, v.158, n.1, p.23-31, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose To report preliminary outcomes of high dose image-guided intensity modulated radiotherapy (IG-IMRT) in the treatment of chordomas of the sacrum, mobile spine and skull base. Methods Retrospective analysis of chordoma patients treated with surgery and/or radiotherapy (RT) in a single tertiary cancer center. Initial treatment was categorized as (A) Adjuvant or definitive high-dose RT (78 Gy/39fx or 24 Gy/1fx) vs (B) surgery-only or low dose RT. The primary endpoint was the cumulative incidence of local failure. Results A total of 31 patients were treated from 2010 through 2020. Median age was 55 years, tumor location was 64% sacrum, 13% lumbar, 16% cervical and 6% clivus. Median tumor volume was 148 cc (8.3 cm in largest diameter), 42% of patients received curative-intent surgery and 65% received primary RT (adjuvant or definitive). 5-year cumulative incidence of local failure was 48% in group A vs 83% in group B (p = 0.041). Tumor size > 330 cc was associated with local failure (SHR 2.2, 95% CI 1.12 to 7.45; p = 0.028). Eight patients developed distant metastases, with a median metastases-free survival of 56.1 months. 5-year survival for patients that received high dose RT was 72% vs 76% in patients that received no or low dose RT (p = 0.63). Conclusion Our study suggests high-dose photon IG-IMRT improves local control in the initial management of chordomas. Health systems should promote reference centers with clinical expertise and technical capabilities to improve outcomes for this complex disease.
Palavras-chave
Chordoma, Intensity modulated radiation therapy (IMRT), Photon
Referências
  1. Bakker SH, 2018, EUR SPINE J, V27, P3043, DOI 10.1007/s00586-018-5764-0
  2. Boriani S, 2006, SPINE, V31, P493, DOI 10.1097/01.brs.0000200038.30869.27
  3. Catton C, 1996, RADIOTHER ONCOL, V41, P67, DOI 10.1016/S0167-8140(96)91805-8
  4. Chen YL, 2013, SPINE, V38, pE930, DOI 10.1097/BRS.0b013e318296e7d7
  5. DeLaney TF, 2009, INT J RADIAT ONCOL, V74, P732, DOI 10.1016/j.ijrobp.2008.08.058
  6. Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
  7. Holliday EB, 2015, SPINE, V40, P544, DOI 10.1097/BRS.0000000000000804
  8. Imai R, 2011, BRIT J RADIOL, V84, pS48, DOI 10.1259/bjr/13783281
  9. Indelicato DJ, 2016, INT J RADIAT ONCOL, V95, P297, DOI 10.1016/j.ijrobp.2016.01.057
  10. Jin CJ, 2020, J NEUROSURG-SPINE, V32, P79, DOI 10.3171/2019.7.SPINE19515
  11. Katsoulakis E, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-150
  12. Laufer I, 2013, J NEUROSURG-SPINE, V18, P207, DOI 10.3171/2012.11.SPINE12111
  13. Munzenrider JE, 1999, STRAHLENTHER ONKOL, V175, P57, DOI 10.1007/BF03038890
  14. Park L, 2006, INT J RADIAT ONCOL, V65, P1514, DOI 10.1016/j.ijrobp.2006.02.059
  15. Ridenour RV, 2010, PEDIATR DEVEL PATHOL, V13, P9, DOI 10.2350/09-01-0584.1
  16. Rotondo RL, 2015, J NEUROSURG-SPINE, V23, P788, DOI 10.3171/2015.3.SPINE14716
  17. Sahgal A, 2015, NEURO-ONCOLOGY, V17, P889, DOI 10.1093/neuonc/nou347
  18. Snider JW, 2018, INT J RADIAT ONCOL, V101, P226, DOI 10.1016/j.ijrobp.2018.01.060
  19. Stacchiotti S, 2015, LANCET ONCOL, V16, pE71, DOI 10.1016/S1470-2045(14)71190-8
  20. Uhl M, 2014, CANCER-AM CANCER SOC, V120, P3410, DOI 10.1002/cncr.28877
  21. Yamada Y, 2013, NEUROSURGERY, V73, P673, DOI 10.1227/NEU.0000000000000083